EGCG treatment in neuroblastoma cells causes phosphorylation of PKC and activation of the nonamyloidogenic α-secretase pathway of APP against Aβ neurotoxicity [175] and EGCG dependent PKC activation induced neuroprotection under 6-OHDA exposure in cells [176]. The gene discussed is PRRT2; the disease is neuroblastoma.